The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2019 | Ublituximab, umbralisib and ibrutinib in CLL and NHL
The combination of ublituximab, umbralisib and ibrutinib was investigated in an open-label, Phase I dose escalation and expansion trial in chronic lymphocytic leukemia or R/R B-cell non-Hodgkin lymphoma (NCT02006485). We spoke to Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX, about the results seen with this chemo-free triplet regimen. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
